COST-EFFECTIVENESS OF TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN INTERMEDIATE-LOW RISK PATIENTS WITH SEVERE AORTIC STENOSIS IN SINGAPORE
Author(s)
Wang P1, Kuntjoro I2, Tay E2, Hon J2, Yip J2, Kong W2, Poh KK2, Yeo TC2, Tan HC2, Celab MG2, Luo N3
1Fudan University, Shanghai, China, 2National University Heart Centre, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore
OBJECTIVES: Transcatheter aortic valve replacement (TAVR) has been mainly advised for inoperable and high surgical risk patients for treating severe aortic stenosis (AS). We conducted cost-effectiveness analysis on TAVR compared with common practice, surgical AVR (SAVR), in intermediate-low risk patients with severe AS in Singapore. METHODS: Due to transfemoral (TF) access being dominant in Singapore, TF-TAVR was used in current analysis. A two-phase economic model combining decision tree and Markov model was developed to assess the incremental cost-effectiveness (ICER) of TF-TAVR versus SAVR over18-year horizon from Singapore healthcare system perspective. Event rates of mortality and complications were estimated from the Placement of Aortic Transcatheter Valves (PARTNER) 2 RCT cohort A and Singapore life table. Cost data were retrieved from the National University Heart Centre database. Health utilities were obtained from Singapore population norm based on EQ-5D. Scenario analyses were conducted using shorter horizon and event rates from PARTNER 2 S3 propensity analysis that used newer TAVR systems. Both one-way and probabilistic sensitivity analyses were performed. RESULTS: In base case scenario, the incremental effectiveness of TAVR versus SAVR is 0.30 QALYs. The ICER of TF-TAVR is S$21,062/QALY. In scenario analysis, where horizon was reduced to 10 years, ICER of TF-TAVR is S$27,060/QALY; where event rates from PARTNER 2 S3 propensity analysis was used, ICER of TF-TAVR is S$16,843/QALY and S$21,378/QALY over 18-year and 10-year horizon, respectively. At a willingness to pay threshold of S$65,000/QALY, TF-TAVR, compared with SAVR, has 99.87% probability of been cost-effective after 10,000 simulations. The model is the most sensitive to cost of TF-TAVI procedure, followed by cost of SAVR procedure. CONCLUSIONS: TF-TAVR seems to be a highly cost-effective option compared to SAVR for intermediate-low surgical risk patients with severe AS in Singapore. Increased procedure experience and/or technology advance may have further increased the cost-effectiveness of TF-TAVR per scenario analysis.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PMD101
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders